Myriad Genetics and Ultima Genomics, a developer of a new ultra-high throughput sequencing platform, announced a joint effort to explore Ultima’s UG 100 sequencing platform and its ppmSeq technology to advance Myriad’s ability to offer groundbreaking clinical tests. Myriad has purchased a new UG 100 that will soon join other leading sequencing platforms in its new Lab of the Future facility in South San Francisco. The Myriad Precise Molecular Residual Disease (MRD) test performs whole-genome sequencing on two samples from cancer patients-one from a tumor and one from normal tissue-to comprehensively identify tumor-specific variants for subsequent tracking in a personalized panel. With Ultima’s support, Myriad will explore the potential for the Precise MRD test to improve in both performance and cost with ppmSeq on the UG 100.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MYGN:
- USPTO issues 3rd patent to Myriad aiding in bringing MRD assay to market
- Myriad Genetics initiated with an Equal Weight at Morgan Stanley
- Myriad Genetics to share new data on genetic testing advancements
- Myriad Genetics study setback unlikely to impact GeneSight, says Leerink
- Myriad Genetics stops GeneSight study over ‘significant disparities’